ENZYME REPLACEMENT THERAPY MARKET ANALYSIS

Enzyme Replacement Therapy MarketSize and Trends

Market Dynamics

Although lysosomal storage disease is a rare disorder, a significant number of people are affected with this disease. According to study published in Molecular Genetics and Metabolism Reports in December 2017, lysosomal storage disease has incidence rate of 1 in 4000 to 1 13,000 live births. Lysosomal storage disease consists of 60 genetic abnormalities with problematic enzyme function. Being an orphan disease condition, regulatory agencies offer the benefit of rapid approval and ease in approval process. This in turn, is expected to expand the overall enzyme replacement therapy market with introduction of new therapies by various key players. For instance, in November 2017, The FDA approved Mepsevii (vestronidase alfa), which is first authorized treatment for pediatric and adult patients suffering from an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII). FDA granted Mepsevii with fast-track approval and orphan drug status to incentivize the development. Financial help by NGOs such as National Gaucher Society help patient receive enzyme replacement therapy that are costly.

Increasing collaborations amongst key companies to fast-track the development of enzymes for replacement is expected to boost growth of the enzyme replacement therapy market size. For instance, in March 2018, Shire plc entered into a preclinical research collaboration with NanoMedSyn— French biotech company—to develop enzyme replacement treatment for a lysosomal storage disorder based on NanoMedSyn’s synthetic derivative technology named AMFA.

Market Taxonomy

On the basis of enzyme type, the global enzyme replacement therapy market is segmented into -:

• Agalsidase Beta
• Velaglucerase Alfa
• Imiglucerase
• Taliglucerase
• Alglucosidase Alfa
• Laronidase
• Idursulfase
• Galsulfase
• Pegademase
• Others

On the basis of indication, the global enzyme replacement therapy market is segmented into -:

• Fabry Disease
• Gaucher Disease
• Pompe Disease
• Scheie Syndrome
• Hunter Disease
• Maroteaux-Lamy Syndrome
• Others

On the basis of end user, the global enzyme replacement therapy market is segmented into -:

• Hospitals
• Clinics
• Home care setting

On the basis of geography, the global enzyme replacement therapy market is segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa